Focal Ablation Therapy for Prostate Cancer: A Literature Review

doi:10.37015/AUDT.2020.200045

Abstract

Abstract:

The incidence and mortality of prostate cancer (PCa) are gradually increasing. Traditional treatments for PCa may result numerous side effects and complications that affect patients’ quality of life. Furthermore, older patients frequently cannot tolerate conventional treatments, such as surgery, chemotherapy, and radiotherapy. Thus, minimally invasive and effective therapeutic approaches for PCa need to be developed for clinical practice. Focal ablation therapy, which uses high temperature to destroy tumors, holds promise as one such approach. It has been applied to PCa in several countries with gradual success and clinical practice This review briefly discusses the application of high-intensity focused ultrasound ablation (HIFU), cryoablation, laser ablation (LA), and radiofrequency and microwave ablation (RFA, MWA) for PCa, including the principles of treatment, clinical effects, and complications. The aim of this review is to provide a reliable reference for the application of focal ablation therapy to PCa.

Key words: Prostate cancer; High-intensity focused ultrasound; Cryoablation; Laser ablation; Radiofrequency ablation; Microwave ablation

Ruiqing Liu, MD, Yaqiong Li, PhD, Bing Mao, MD, Na Li, PhD, Shaobo Duan, MD, Zhiyang Chang, MS, Ye Zhang, MS, Shuaiyang Wang, MS, Lianzhong Zhang, MD. Focal Ablation Therapy for Prostate Cancer: A Literature Review. Advanced Ultrasound in Diagnosis and Therapy, 2020, 4(4): 308-314.

References

[1]	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66:115-132.
[2]	Ratcliff CG, Cohen L, Pettaway CA, Parker PA. Treatment regret and quality of life following radical prostatectomy. Support Care Cancer 2013; 21:3337-3343.
[3]	Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358:1250-1261.
[4]	Hoffman RM, Lo M, Clark JA, Albertsen PC, Barry MJ, Goodman M, et al. Treatment decision regret among long-term survivors of localized prostate cancer: results from the prostate cancer outcomes study. J Clin Oncol 2017; 35:2306-2314.
[5]	Sanchez-Salas R, de la Rosette J, Polascik TJ, Carneiro A, Sivaraman A, Cathelineau X, et al. Focal therapy for prostate cancer: a more vehement view of the approach could translate into real benefits for our patients. Eur Urol 2018; 74:537-539.
[6]	Marshall S, Taneja S. Focal therapy for prostate cancer: The current status. Prostate Int 2015; 3:35-41.
[7]	Bozzini G, Colin P, Nevoux P, Villers A, Mordon S, Betrouni N. Focal therapy of prostate cancer: energies and procedures. Urol Oncol 2013; 31:155-167.
[8]	Kennedy JE. High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer 2005; 5:321-327.
[9]	Bihrle R, Foster RS, Sanghvi NT, Donohue JP, Hood PJ. High intensity focused ultrasound for the treatment of benign prostatic hyperplasia: early United States clinical experience. J Urol 1994; 151:1271-1275.
[10]	Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995; 55:3346-3351.
[11]	Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, et al. Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting. Eur Urol 2015; 67:771-777.
[12]	Acher PL, Hodgson DJ, Murphy DG, Cahill DJ. High-intensity focused ultrasound for treating prostate cancer. BJU Int 2007; 99:28-32.
[13]	Thuroff S, Chaussy C, Vallancien G, Wieland W, Kiel HJ, Le Duc A, et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 2003; 17:673-677.
[14]	Gelet A, Chapelon JY, Bouvier R, Rouviere O, Lasne Y, Lyonnet D, et al. Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol 2000; 14:519-528.
[15]	Uchida T, Sanghvi NT, Gardner TA, Koch MO, Ishii D, Minei S, et al. Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report. Urology 2000; 59 398-399.
[16]	Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, et al. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 2008; 53:1194-1201.
[17]	Ahmed HU, Freeman A, Kirkham A, Sahu M, Scott R, Allen C, et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol. 2011; 185:1246-1254.
[18]	Chen PY, Chiang PH, Liu YY, Chuang YC, Cheng YT. Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence. Int J Urol 2018; 25:615-620.
[19]	Gill IS, Azzouzi AR, Emberton M, Coleman JA, Coeytaux E, Scherz A, et al. Randomized trial of partial gland ablation with vascular targeted phototherapy versus active surveillance for low risk prostate cancer: Extended followup and analyses of effectiveness. J Urol 2018; 200:786-793.
[20]	Tay KJ, Cheng CWS, Lau WKO, Khoo J, Thng CH, Kwek JW. Focal therapy for prostate cancer with in-bore mr-guided focused ultrasound: two-year follow-up of a phase I trial-complications and functional outcomes. Radiology 2017; 285:620-628.
[21]	Ghai S, Perlis N, Lindner U, Hlasny E, Haider MA, Finelli A, et al. Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial. Eur Radiol 2018; 28:4281-4287.
[22]	Chaussy C, Thuroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 2003; 4:248-252.
[23]	Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J Urol 1999; 161:156-162.
[24]	Han KR, Belldegrun AS. Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int 2004; 93:14-18.
[25]	Babaian RJ, Donnelly B, Bahn D, Baust JG, Dineen M, Ellis D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 2008; 180:1993-2004.
[26]	Soanes WA, Gonder MJ, Shulman S. Apparatus and technique for cryosurgery of the prostate. J Urol 1966; 96:508-511.
[27]	Reuter HJ. Endoscopic cryosurgery of prostate and bladder tumors. J Urol 1972; 107:389-393.
[28]	Flocks RH, Nelson CM, Boatman DL. Perineal cryosurgery for prostatic carcinoma. J Urol 1972; 108:933-935.
[29]	Porter MP, Ahaghotu CA, Loening SA, See WA. Disease-free and overall survival after cryosurgical monotherapy for clinical stages B and C carcinoma of the prostate: a 20-year followup. J Urol 1997; 158:1466-1469.
[30]	Woodrum DA, Kawashima A, Gorny KR, Mynderse LA. Prostate cancer: state of the art imaging and focal treatment. Clin Radiol 2017; 72:665-679.
[31]	Onik GM, Cohen JK, Reyes GD, Rubinsky B, Chang Z, Baust J. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer 1993; 72:1291-1299.
[32]	Jacome-Pita F, Sanchez-Salas R, Barret E, Amaruch N, Gonzalez-Enguita C, Cathelineau X. Focal therapy in prostate cancer: the current situation. Ecancermedicalscience 2014; 8:435.
[33]	Shinohara K, Connolly JA, Presti JC, Jr., Carroll PR. Cryosurgical treatment of localized prostate cancer (stages T1 to T4): preliminary results. J Urol 1996; 156: 115-120; discussion 120-111.
[34]	Bahn DK, Lee F, Solomon MH, Gontina H, Klionsky DL, Lee FT, Jr. Prostate cancer: US-guided percutaneous cryoablation. Work in progress. Radiology 1995; 194:551-556.
[35]	Cohen JK, Miller RJ, Rooker GM, Shuman BA. Cryosurgical ablation of the prostate: two-year prostate-specific antigen and biopsy results. Urology 1996; 47:395-401.
[36]	Chin JL, Al-Zahrani AA, Autran-Gomez AM, Williams AK, Bauman G. Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). J Urol 2012; 188:1170-1175.
[37]	Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, Pisters LL, Katz AE. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol 2008; 180:554-558.
[38]	Guo Z, Si T, Yang X, Xu Y. Oncological outcomes of cryosurgery as primary treatment in T3 prostate cancer: experience of a single centre. BJU Int 2015; 116:79-84.
[39]	Long JP, Fallick ML, LaRock DR, Rand W. Preliminary outcomes following cryosurgical ablation of the prostate in patients with clinically localized prostate carcinoma. J Urol 1998; 159:477-484.
[40]	Robinson JW, Donnelly BJ, Siever JE, Saliken JC, Ernst SD, Rewcastle JC, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer 2009; 115:4695-4704.
[41]	Bales GT, Williams MJ, Sinner M, Thisted RA, Chodak GW. Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy. Urology 1995; 46:676-680.
[42]	Izzo F. Other thermal ablation techniques: microwave and interstitial laser ablation of liver tumors. Ann Surg Oncol 2003; 10:491-497.
[43]	Tranberg KG. Percutaneous ablation of liver tumours. Best Pract Res Clin Gastroenterol 2004; 18:125-145.
[44]	Veenendaal LM, de Jager A, Stapper G, Borel Rinkes IH, van Hillegersberg R. Multiple fiber laser-induced thermotherapy for ablation of large intrahepatic tumors. Photomed Laser Surg 2006; 24:3-9.
[45]	Germer CT, Roggan A, Ritz JP, Isbert C, Albrecht D, Muller G, et al. Optical properties of native and coagulated human liver tissue and liver metastases in the near infrared range. Lasers Surg Med 1998; 23:194-203.
[46]	Whelan WM, Wyman DR, Wilson BC. Investigations of large vessel cooling during interstitial laser heating. Med Phys 1995; 22:105-115.
[47]	Solon LR, Aronson R, Gould G. Physiological implications of laser beams. Science 1961; 134:1506-1508.
[48]	Muschter R, Hofstetter A. Interstitial laser therapy outcomes in benign prostatic hyperplasia. J Endourol 1995; 9:129-135.
[49]	Bown SG. Phototherapy in tumors. World J Surg 1983; 7:700-709.
[50]	Lindner U, Weersink RA, Haider MA, Gertner MR, Davidson SR, Atri M, et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol 2009; 182:1371-1377.
[51]	Lindner U, Lawrentschuk N, Weersink RA, Davidson SR, Raz O, Hlasny E, et al. Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. Eur Urol 2010; 57:1111-1114.
[52]	Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, Stadler WM, et al. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology 2013; 267:932-940.
[53]	Natarajan S, Raman S, Priester AM, Garritano J, Margolis DJ, Lieu P, et al. Focal laser ablation of prostate cancer: Phase I clinical trial. J Urol 2016; 196:68-75.
[54]	Eggener SE, Yousuf A, Watson S, Wang S, Oto A. Phase II Evaluation of magnetic resonance imaging guided focal laser ablation of prostate cancer. J Urol 2016; 196:1670-1675.
[55]	Natarajan S, Jones TA, Priester AM, Geoghegan R, Lieu P, Delfin M, et al. Focal laser ablation of prostate cancer: feasibility of magnetic resonance imaging-ultrasound fusion for guidance. J Urol 2017; 198:839-847.
[56]	Schulman CC, Zlotta AR. Transurethral needle ablation of the prostate (TUNA): pathological, radiological and clinical study of a new office procedure for treatment of benign prostatic hyperplasia using low-level radiofrequency energy. Semin Urol 1994; 12:205-210.
[57]	Strohmaier WL, Bichler KH, Bocking A, Fluchter SH. Histological effects of local microwave hyperthermia in prostatic cancer. Int J Hyperthermia 1991; 7:27-33.
[58]	Van Cauwelaert RR, Castillo OC, Aquirre CA, Azocar GH, Medina FI. Transurethral microwave thermotherapy for the treatment of benign prostatic hyperplasia: preliminary experience. Eur Urol 1993; 23:282-284.
[59]	Djavan B, Zlotta AR, Susani M, Heinz G, Shariat S, Silverman DE, et al. Transperineal radiofrequency interstitial tumor ablation of the prostate: correlation of magnetic resonance imaging with histopathologic examination. Urology 1997; 50 992-983; discussion 992-983.
[60]	Zlotta AR, Djavan B, Matos C, Noel JC, Peny MO, Silverman DE, et al. Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br J Urol 1998; 81:265-275.
[61]	Wu KJ, Qi DF, Li X. Transperineum RF multi-hook probe interstitial ablation for treatment of begin prostatic hyperplasia (BPH) and prostatic cancer (PC). China Journal of Modern Medicine 2002; 12:4.
[62]	Hu ZQ, Ma YZ, Ye Z, Du GH, Guo XL, Song XD, et al. Mutipolar rasiofrequency thermal ablation for the treatment of prostate carcinoma (Report 5 cases). Journal of Clinical Urology 2003; 18:276-277.
[63]	Shariat SF, Raptidis G, Masatoschi M, Bergamaschi F, Slawin KM. Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. Prostate 2005; 65:260-267.
[64]	Ma BJ, Xu Y, Niu YJ, Chang JW, Zhang SM, Ma TX. Transrectal ultrasound (TRUS) guided transperineal radiofrequency ablation of prostate carcinoma. Xiandai Miniao Waike Zazhi 2006; 11:32-34.
[65]	Zhang L, Wang LG, Fan WJ, Ouyang YS. CT-guided percutaneous multipolar rasiofrequency ablaiton for carcinoma of prostate. Guangzhou Medicine 2009; 40:11-13.
[66]	Xu EJ, li K, Zheng RQ, Su ZZ, Si TJ, Sun QP, et al. The preliminary study of radiofrequency ablation in combination with hormonal therapy for the treatment of intermediate and advanced prostate cancer. Chin J Endourology (Electronic Edition) 2012; 6:53-54.
[67]	Liu R, Duan S, Cao H, Cao G, Chang Z, Zhang Y, et al. A pilot study of the shapes of ablation lesions in the canine prostate by laser, radiofrequency and microwave and their clinical significance. PLoS One 2020; 15(4):e0223229.
[68]	Ouzzane A, Betrouni N, Valerio M, Rastinehad A, Colin P, Ploussard G. Focal therapy as primary treatment for localized prostate cancer: definition, needs and future. Future Oncol 2017; 13:727-741.
[69]	Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med 2009; 361:1704-1706.
[70]	Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis 2011; 14:46-52.
[71]	Radtke JP, Schwab C, Wolf MB, Freitag MT, Alt CD, Kesch C, et al. Multiparametric magnetic resonance imaging (MRI) and MRI-transrectal ultrasound fusion biopsy for index tumor detection: Correlation with radical prostatectomy specimen. Eur Urol 2016; 70:846-853.
[72]	Valerio M, Shah TT, Shah P, McCartan N, Emberton M, Arya M, et al. Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study. Urol Oncol 2017; 35:150 e151-150 e157.